AM declares grants (paid to his institution) from GILEAD for work related to this topic; consulting fees from Merck for work unrelated to this topic; honoraria for lectures or presentations from Takeda (for work unrelated to this topic) and Bristol Myers Squibb (for work related to this topic); support for attending meetings from Jazz Pharmaceuticals (for work unrelated to this topic) and Gilead (for work related to this topic); and participation on advisory boards of Novartis (for work related to this topic) and Merck (for work unrelated to this topic). AS declares consulting fees from Takeda (for work unrelated to this topic), Novartis (for work related to this topic), Gilead Kite (for work related to this topic), Bristol Myers Squibb–Celgene (for work related to this topic), Sanofi (for work unrelated to this topic), Jazz Pharmaceuticals (for work unrelated to this topic), and Vertex (for work unrelated to this topic); support for attending meetings from Gilead Kite and Novartis (for work related to this topic); and participation on advisory boards of Gilead Kite (for work related to this topic), Novartis (for work related to this topic), Bristol Myers Squibb–Celgene (for work related to this topic), Takeda (for work unrelated to this topic), GenMab (for work unrelated to this topic), Astra Zeneca (for work unrelated to this topic), Sanofi (for work unrelated to this topic), and Janssen (for work unrelated to this topic).